Advertisement

Drug Investigation

, Volume 3, Supplement 4, pp 3–11 | Cite as

Overview of Fosinopril

A Novel ACE Inhibitor
  • Michael A. Weber
Article

Summary

Fosinopril is a prodrug of the active diacid compound, fosinoprilat. Fosinopril is the first of a new chemical class of angiotensin-converting enzyme (ACE) inhibitors, the phosphinic acids, and is indicated for the once-daily treatment of mild-to-moderate essential hypertension.

Following oral administration, fosinopril effectively lowers systolic and diastolic blood pressure for 24 hours. Short term (8- to 12-week) clinical trials have shown fosinopril 10 to 40mg once daily to be significantly more effective than placebo and comparable to propranolol 40 to 80mg twice daily in the treatment of patients with mild-to-moderate or moderate-to-severe essential hypertension unresponsive to diuretic monotherapy. In a 12-week trial, fosinopril once daily and enalapril once daily produced equivalent antihypertensive effects in patients with mild-to-moderate essential hypertension. In elderly patients with mild-to-moderate hypertension, fosinopril lowered blood pressure as effectively as nifedipine sustained release (SR) and appears to have been better tolerated.

Fosinopril was well tolerated by patients in clinical trials, and the incidence of adverse events was similar to that observed with placebo, propranolol or enalapril. Headache, cough, and dizziness were reported most often, but these symptoms are typical of ACE inhibitors as a class. Fosinopril appears to have a low potential for drug interactions.

The unique characteristic of fosinopril is its dual route of elimination, which is equally balanced between the renal and hepatic routes in patients with normal kidney function. Moreover, there is evidence that in patients with renal dysfunction, a compensatory shift towards increased elimination by the liver takes place, thereby reducing the risk of drug accumulation. This feature distinguishes fosinopril from nearly all long-acting ACE inhibitors, which are eliminated primarily by the kidney and which may require adjustment of the initial dose for varying degrees of renal dysfunction. Fosinopril’s dual compensatory elimination makes it a novel compound suitable for a wide range of hypertensive patients, including elderly patients and those with declining renal function. Dual elimination may also reduce the risk of adverse drug experiences related to drug accumulation and allows a simplified dosing regimen regardless of renal function.

Keywords

Nifedipine Enalapril Essential Hypertension Lisinopril Drug Invest 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson RJ, Duchin KL, Gore RD, et al. Once-daily fosinopril in the treatment of hypertension. Hypertension 17: 636–642, 1991PubMedCrossRefGoogle Scholar
  2. Brunner HR, Nussberger J, Waeber B. The present molecules of converting enzyme inhibitors. Journal of Cardiovascular Pharmacology 7 (Suppl. 1): S2–S11, 1985PubMedCrossRefGoogle Scholar
  3. Cirillo VJ, Till AE, Gomez HJ, et al. Effect of age on lisinopril pharmacokinetics. (Abstract). Clinical Pharmacology and Therapeutics 39: 187, 1986Google Scholar
  4. Clementy J. Double-blind, randomised study of fosinopril versus nifedipine SR in the treatment of mild-to-moderate hypertension in elderly patients. Drug Investigation 3 (Suppl. 4): 45–53, 1991Google Scholar
  5. Creasey WA, Brennan J, McKinstry DN, Fordtran JS. Absorption of fosinopril from various sites within the gastrointestinal tract. Acta Pharmacologica et Toxicologica 59 (Suppl. 5): 83, 1986Google Scholar
  6. Cushman DW, Wang FL, Fung WC, et al. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. American Journal of Hypertension 2: 294–306, 1989PubMedGoogle Scholar
  7. Davies RO, Gomez JH, Irvin JD, Walker JF. An overview of the clinical pharmacology of enalapril. British Journal of Clinical Pharmacology 18: 215S–229S, 1984PubMedCrossRefGoogle Scholar
  8. Debusman ER, Pujadas JO, Lahn W, et al. Influence of renal function on the pharmacokinetics of ramipril (HOE 498). American Journal of Cardiology 59: 79D–80D, 1987CrossRefGoogle Scholar
  9. Duchin K, Tu J, Frantz M, et al. Pharmacodynamics and pharmacokinetics of SQ 28.555 (SQ), a new angiotensin-converting enzyme inhibitor, in healthy subjects. (Abstract.) Clinical Pharmacology and Therapeutics 37: 192, 1985Google Scholar
  10. Duchin KL, Waclawski AP, Tu JI, et al. Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects. Journal of Clinical Pharmacology 31: 58–64, 1991PubMedGoogle Scholar
  11. Fruncillo RJ, Rocci ML, Vlasses PH, et al. Disposition of enalapril and enalaprilat in renal insufficiency. Kidney International 31 (Suppl. 20): 117–122, 1987Google Scholar
  12. Goldstein RJ. A multicentre randomised double-blind parallel comparison of fosinopril sodium and enalapril maleate for the treatment of mild-to-moderate essential hypertension. Drug Investigation 3 (Suppl. 4): 38–44, 1991Google Scholar
  13. Horvath AM, Olsen SC, Ferry JJ, et al. Pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients with renal insufficiency. Journal of Clinical Pharmacology 28: 918, 1988Google Scholar
  14. Kaiser G, Ackermann R, Sioufi A. Pharmacokinetics of a new angiotensin converting enzyme inhibitor, benazapril hydrochloride, in special populations. American Heart Journal 117: 746–750, 1989PubMedCrossRefGoogle Scholar
  15. Kostis JB. Angiotensin-converting enzyme inhibitors. Emerging differences and new compounds. American Journal of Hypertension 2: 57–64, 1989PubMedGoogle Scholar
  16. Larmour I, Jackson B, Cubela R, Johnston CI. Enalapril (MK 421) activation in man: importance of liver status. British Journal of Clinical Pharmacology 19: 701–704, 1985PubMedCrossRefGoogle Scholar
  17. Lees KR, Green ST, Reid JL. Influence of age on the pharmacokinetics and pharmacodynamics of perindopril. Clinical Pharmacology and Therapeutics 44: 418–425, 1988PubMedCrossRefGoogle Scholar
  18. Levinson B, Sugarman AA, Couchman T, et al. Advanced age per se has no influence on the kinetics of the active diacid of fosinopril. Journal of Clinical Pharmacology 26: 555, 1986Google Scholar
  19. Macdonald NJ, Elliott HL, Howie CH, et al. Age and the pharmacodynamics and pharmacokinetics of benazepril. British Journal of Clinical Pharmacology 27 (Suppl.): 707P–708P, 1988Google Scholar
  20. Mackaness GB. The future of angiotensin-converting enzyme inhibitors. Journal of Cardiovascular Pharmacology 7 (Suppl. 1): S30–S34, 1985PubMedCrossRefGoogle Scholar
  21. MacLeod CM, Bartley EA, Kripalani KJ, Marino MR. Effect of hepatic function on disposition of fosinopril in humans. Abstract. Journal of Clinical Pharmacology 30: 839, 1990Google Scholar
  22. McAreavey D, Robertson JIS. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs 40(3): 326–345, 1990PubMedCrossRefGoogle Scholar
  23. Miller WE. Randomised, double-blind, comparison of fosinopril and propranolol added to diuretic therapy for the treatment of moderate-to-severe hypertension. Drug Investigation 3 (Suppl. 4): 32–37, 1991Google Scholar
  24. Ondetti MA. Structural relationships of angiotensin-converting enzyme inhibitors to pharmacologic activity. Circulation 77 (Suppl. 1): 174–178, 1988Google Scholar
  25. Oren S, Messerli FH, Grossman E, Garavaglia GE, Frohlich ED. Intermediate and short-term cardiovascular effects of fosinopril, a new angiotensin-converting-enzyme inhibitor, in patients with essential hypertension. Journal of the American College of Cardiology 17: 1183–1187, 1991PubMedCrossRefGoogle Scholar
  26. Perindopril (Coversyl) product monograph, Adis Press 15, 1989Google Scholar
  27. Petrillo Jr EW, Powell JR, Cushman DW, et al. Angiotensin-converting enzyme inhibitors: accomplishments and challenges. Clinical and Experimental Hypertension Part A — Theory and Practice 9: 235–241, 1987CrossRefGoogle Scholar
  28. Rakhit A, Kochak GM, Tipnis V, et al. Pharmacokinetics of pentopril in the elderly. British Journal of Clinical Pharmacology 24: 351–357, 1987PubMedCrossRefGoogle Scholar
  29. Reid JL, Macdonald NJ, Lees KR, et al. Angiotensin-converting enzyme inhibitors in the elderly. American Heart Journal 117: 751–755, 1989PubMedCrossRefGoogle Scholar
  30. Salvetti A. Newer ACE inhibitors: a look at the future. Drugs 40(6): 800–828, 1990PubMedCrossRefGoogle Scholar
  31. Savage DD, Drayer JM, Henry WL, et al. Echocardiographic assessment of cardiac anatomy and function in hypertensive subjects. Circulation 59: 623–632, 1979PubMedCrossRefGoogle Scholar
  32. Shionoiri H, Gotoh E, Takagi N, et al. Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal and impaired renal function. Journal of Cardiovascular Pharmacology 11: 242–249, 1988PubMedGoogle Scholar
  33. Sica DA, Cutler RE, Palmer RJ, Ford NF. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Clinical Pharmacokinetics 20: 420–427, 1991PubMedCrossRefGoogle Scholar
  34. Singhvi SM, Duchin KL, Morrison RA, et al. Disposition of fosinopril sodium in healthy subjects. British Journal of Clinical Pharmacology 25: 9–15, 1988PubMedCrossRefGoogle Scholar
  35. van Shaik BAM, Geyskes GG, van der Wouw PA, et al. Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function. European Journal of Clinical Pharmacology 34: 61–65, 1988CrossRefGoogle Scholar
  36. Waldemar G, Ibsen H, Strandgaard S, et al. The effect of fosinopril sodium on cerebral blood flow in moderate essential hypertension. American Journal of Hypertension 3: 464–470, 1990PubMedGoogle Scholar
  37. Waldemar G, Paulson OB. Angiotensin converting enzyme inhibition and cerebral circulation — a review. British Journal of Clinical Pharmacology 28: 177S–182S, 1989PubMedCrossRefGoogle Scholar
  38. Ward TD. The additive effect of fosinopril in patients taking chlorthalidone for the treatment of mild-to-moderate essential hypertension: a multicentre, placebo-controlled, dose-response study. Drug Investigation 3 (Suppl. 4): 25–31, 1991Google Scholar
  39. Zusman RM, Christensen DM, Higgins J, et al. Fosinopril improves left ventricular systolic and diastolic function. Clinical Research 38: 554A, 1990Google Scholar

Copyright information

© Adis International Limited 1991

Authors and Affiliations

  • Michael A. Weber
    • 1
  1. 1.Veterans Administration Medical CenterLong BeachUSA

Personalised recommendations